Maraviroc in Rheumatoid Arthritis

Phase 2 Terminated 128 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate whether maraviroc, an investigational drug given with methotrexate (MTX) is safe and effective in the treatment of rheumatoid arthritis in adult patients.

Timeline

Start: 2007-02
Primary completion: 2008-10
Completion: 2008-10

Outcome

Missed primary endpoint

Stopped: “See Detailed Description.”

registry Maraviroc 300 mg BID (POC) vs Placebo (POC); p = 0.155; Percentage Difference 9.09 (90% CI -6.16 to 21.83) NCT00427934 ↗

paper There was no significant difference in the number of ACR20 responders between the maraviroc (23.7%) and placebo (23.8%) groups PMID 22251436 ↗

Publications

Fleishaker DL, Garcia Meijide JA, Petrov A, Kohen MD, Wang X, Menon S, Stock TC, Mebus CA, Goodrich JM, Mayer HB, Zeiher BG. Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial. Arthritis Res Ther. 2012 Jan 17;14(1):R11. doi: 10.1186/ar3685.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Maraviroc	Other / unclassified	150 mg	Oral
Subject	Maraviroc	Other / unclassified	300 mg	Oral